Schizophrenia [1, 10]Epilepsy [1, 17]Progressive myoclonic epilepsy [1, 17]Developmental and epileptic encephalopathy [1, 17]Hearing loss [1, 13]Tinnitus [10]Alzheimer's disease [1]Fragile X syndrome [13]Ataxia [1, 15]Cognitive impairment [2, 14]
04
Interacting drugs
AUT00063 [10]
7 more in the full profile.
Beyond the preview
Go deeper on Potassium voltage-gated channel subfamily C member 1 and Potassium voltage-gated channel subfamily C member 2 (Kv3.1/Kv3.2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Full profile access
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Full profile access
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Full profile access
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Full profile access
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Full profile access
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Full profile access
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Potassium voltage-gated channel subfamily C member 1 and Potassium voltage-gated channel subfamily C member 2 (Kv3.1/Kv3.2).